Edward Carr

GROUP LEADER

Ed completed an MB/PhD at Trinity Hall, Cambridge and post-graduate medical training in nephrology and general medicine in Cambridge and nearby hospitals. After his PhD with Prof Ken Smith, he spent his academic training posts with Dr Michelle Linterman’s group at the Babraham Institute.

His lab’s work focuses on the heterogeneity of immune responses between individuals, both at times of health and disease. The lab studies antibody responses after vaccination as a route to better understand their selection after any antigen encounter.

Ed is supported by an MRC clinician scientist fellowship, and his group is seconded to the Crick.

Links

Qualifications and history

2012
University of Cambridge
MB/PhD
2012
University of Cambridge
Academic Foundation Programme
2014
University of Cambridge
Academic Clinical Fellowship
2016
University of Cambridge
Clinical Lecturer
2020
The Francis Crick Institute
Postdoctoral Clinical Fellow
2023
UCL
MRC Clinician Scientist Fellowship
2024
Royal Free Hospital
Honorary Consultant Nephrologist
2024
The Francis Crick Institute
Seconded Group Leader

Crick Pre-Crick

Displaying 1 - 20 of 53
Last updated : 03 March 2026 03:34

Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosis

Authors (34)
BMJ Neurology Open
Published
Crick labs/ facilities
Full details

Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses

Authors (38)
Journal of Infection
Published
Crick labs/ facilities
Full details

Improved resolution of influenza vaccination responses with high-throughput live virus microneutralisation

Authors (20)
Influenza and Other Respiratory Viruses
Published
Crick labs/ facilities
Full details

SARS-CoV-2 antibody immunity across three continents: the West Africa, West Indies, West London Consortium

Preprint
Authors (20)
  • David Greenwood
  • Oliver Hague
  • Eliza Mari Kwesi-Maliepaard
  • Shanice A Redman
  • Crick Serology Consortium
  • The HERITAGE study team
  • [...]
  • Christine VF Carrington
  • Adam Kucharski
  • Peter K Quashie
  • Emma Wall
  • Mary Wu
medRxiv
Published
Crick labs/ facilities
Full details

Adults in Ghana generate higher and more durable neutralising antibody titres following primary course COVID-19 vaccination than matched UK adults: The HERITAGE Study

Authors (32)
  • Eliza Mari Kwesi-Maliepaard
  • Yakubu Alhassan
  • Emmanuel K Quaye
  • Vera M Kotey
  • Aisha M Mohammed
  • Seth Agyemang
  • [...]
  • Kwame Amponsa-Achiano
  • Franklin Asiedu Bekoe
  • Gordon Awandare
  • Peter K Quashie
  • Yaw Bediako
BMC Medicine
Published
Crick labs/ facilities
Full details

Investigation of influenza A(H5N1) virus neutralization by quadrivalent seasonal vaccines, United Kingdom, 2021–2024

Authors (14)
Emerging Infectious Diseases
Published
Crick labs/ facilities
Full details

Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics

Authors (20)
Vaccine
Published
Crick labs/ facilities
Full details

Chronogram: an R package for data curation and analysis of infection and vaccination cohort studies

Authors (13)
Bioinformatics Advances
Published
Crick labs/ facilities
Full details

Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study

Authors (44)
  • Timothy W Russell
  • Hermaleigh Townsley
  • Joel Hellewell
  • Joshua Gahir
  • Marianne Shawe-Taylor
  • David Greenwood
  • [...]
  • Mary Wu
  • David LV Bauer
  • Edward Carr
  • Emma Wall
  • Adam J Kucharski
The Lancet Infectious Diseases
Published
Crick labs/ facilities
Full details

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial

Authors (48)
  • Carl S Goodyear
  • Amit Patel
  • Eleanor Barnes
  • Michelle Willicombe
  • Stefan Siebert
  • Thushan I de Silva
  • [...]
  • David Thomas
  • Amanda Kirkham
  • Iain B McInnes
  • Pamela Kearns
  • OCTAVE-DUO investigators
The Lancet Rheumatology
Published
Crick labs
Full details

COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history

Authors (37)
PLOS ONE
Published
Crick labs/ facilities
Full details

Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign

Authors (22)
The Lancet
Published
Crick labs/ facilities
Full details

Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants

Authors (26)
PLOS Biology
Published
Crick labs/ facilities
Full details

SARS-CoV-2 mucosal neutralising immunity after vaccination

Authors (38)
The Lancet Infectious Diseases
Published
Crick labs/ facilities
Full details